These insights into the mechanism of IgAse open multiple therapeutic avenues, including inhibitor development for anti-pathogen strategies and novel approaches for treating diseases driven by pathological IgA depositions, such as IgA nephropathy, through the design of improved IgAse variants with enhanced functionalities. This evidence concerns the gene CD79A and IgA glomerulonephritis.